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Abstract
Background: The study investigated whether donepezil exerts symptomatic benefit in patients with posterior cortical
atrophy (PCA), an atypical variant of Alzheimer’s disease.
Methods: A single-centre, double-blind, placebo-controlled, cross-over clinical trial was performed to assess the efficacy
of donepezil in patients with PCA. Each patient received either donepezil (5 mg once daily in the first 6 weeks and 10 mg
once daily in the second 6 weeks) or placebo for 12 weeks. After a 2-week washout period, each patient received the
other treatment arm during the following 12 weeks followed by another 2-week washout period. The primary outcome
was the Mini-Mental State Examination (MMSE) at 12 weeks. Secondary outcome measures were five
neuropsychological tests reflecting parieto-occipital function. Intention-to-treat analysis was used. For each
outcome measure, carry-over effects were first assessed. If present, then analysis was restricted to the first 12-
week period. Otherwise, the standard approach to the analysis of a 2 × 2 cross-over trial was used.
Results: Eighteen patients (13 females) were recruited (mean age 61.6 years). There was a protocol violation in one
patient, who subsequently withdrew from the study due to gastrointestinal side effects. There was statistically significant
(p < 0.05) evidence of a carry-over effect on MMSE. Therefore, the analysis of treatment effect on MMSE was restricted to
the first 12-week period. Treatment effect at 6 weeks was statistically significant (difference = 2.5 in favour of donepezil,
95% CI 0.1 to 5.0, p < 0.05). Treatment effect at 12 weeks was close, but not statistically significant (difference = 2.0 in
favour of donepezil, 95% CI –0.1 to 4.5, p > 0.05). There were no statistically significant treatment effects on any of the
five neuropsychological tests, except for digit span at 12 weeks (higher by 0.5 digits in favour of placebo, 95% CI 0.1 to 0.
9). Gastrointestinal side effects occurred most frequently, affecting 13/18 subjects (72%), and were the cause of study
discontinuation in one subject. Nightmares and vivid dreams occurred in 8/18 subjects (44%), and were statistically more
frequent during treatment with donepezil.
Conclusions: In this small study, there was no statistically significant treatment effect of donepezil on the primary
outcome measure (MMSE score at 12 weeks) in PCA patients, who appear to be particularly susceptible to the
development of nightmares and vivid dreams when treated.
Trial registration: Trial registration: Current Controlled Trials ISRCTN22636071. Retrospectively registered 19 May 2010
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Background
Alzheimer’s disease (AD) typically presents with progres-
sive impairment of episodic memory as a result of de-
generation of medial temporal lobe structures before the
involvement of other cortical regions causing widespread
global cognitive impairment. Cholinesterase inhibitors
(AChEI) have been shown to provide symptomatic bene-
fit in patients with mild to moderate AD [1]. A small
but significant proportion of patients with AD-type
pathology present with visual perceptual or visual spatial
dysfunction, apraxia, dyscalculia or alexia reflecting pos-
terior cortical dysfunction, with relative preservation of
episodic memory. Structural brain imaging in these pa-
tients reveals parieto-occipital atrophy (posterior cortical
atrophy (PCA)) [2]. Only one case report suggested po-
tential therapeutic benefit from taking AChEI in a pa-
tient with PCA [3]. Otherwise, there have been no
studies assessing the effectiveness of AChEI specifically
in patients with PCA due to underlying AD.
Methods
Study aim
This study assessed the efficacy of donepezil, a licensed
AChEI, in patients with PCA due to underlying AD.
Study design
This is a single-centre, double-blind, placebo-controlled,
cross-over clinical trial assessing the efficacy of donepe-
zil in patients with PCA presumed to be due to under-
lying AD. The study was approved by the Local Ethics
Committee and was subject to inspection by the Medi-
cines and Healthcare Products Regulatory Agency in the
UK. The study was conducted during the period April
2003–December 2011. Both patients and clinical investi-
gators remained blinded to study treatment for the
whole duration of the study, even after the statistical
analysis of the whole study was completed.
The study timeline is shown in Fig. 1. During the first
treatment period (weeks 1–12), patients were rando-
mised to receive either donepezil or placebo. During the
first 6 weeks of the first treatment period (weeks 1–6),
patients received either donepezil 5 mg once daily or
placebo once daily (level-one treatment). During the fol-
lowing 6 weeks of the first treatment period (weeks 7–
12), the dose of donepezil was increased to 10 mg once
daily in the active treatment arm or patients were con-
tinued on placebo in the placebo arm (level-two treat-
ment). The first treatment period was followed by a 2-
week washout period (weeks 13–14). During the second
treatment period (weeks 15–26) the treatment arms
were crossed over using a similar dose escalation as in
the first treatment period: that is, level-one treatment
during the first 6 weeks (weeks 15–20) and level-two
treatment during the following 6 weeks (weeks 21–26).
The second treatment period was followed by a second
2-week washout period (weeks 27–28).
Study participants
Patients with a clinical diagnosis of PCA due to under-
lying AD were recruited from the Cognitive Disorders
Clinic at the National Hospital for Neurology and
Neurosurgery, London, UK. Patients with clinical fea-
tures or work-up suggestive of an underlying pathology
other than AD (dementia with Lewy bodies, corticobasal
degeneration, prion disease) were excluded (e.g. visual
hallucinations, reduplicative phenomena, parkinsonism,
alien limb syndrome, asymmetric dystonia and myoclo-
nus, ataxia). All patients signed consent forms with
assent from the next of kin. At the time of study design,
there were no published clinical criteria for the diagnosis
of PCA. Instead, all patients met the inclusion and ex-
clusion criteria presented in Table 1. Retrospectively, all
patients met the Mendez et al. and Tang-Wai et al. cri-
teria for PCA [4, 5].
Fig. 1 DONIPAD study timeline. DONIPAD DONepezil In Posterior cortical atrophy due to underlying Alzheimer’s Disease
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Outcome measures
The primary end point was change in the Mini-Mental
State Examination (MMSE) score at 12 weeks [6]. The
MMSE has been used as a cognitive outcome measure
in studies assessing the efficacy of cholinesterase inhibi-
tors in AD [7]. The MMSE has also been used clinically
to assess eligibility for treatment with a cholinesterase
inhibitor [8]. The MMSE is relatively short to administer
and so can be conveniently administered repeatedly over
a 28-week study period. We used the same three words
for testing word repetition and verbal recall throughout.
Although this increases the risk of learning effects on re-
peated testing, it maintains consistency in the level of
test difficulty throughout the study. Secondary end
points were five tests reflecting parieto-occipital func-
tion: number location test [9]; simple calculation test
(unpublished data); letter cancellation test [10]; dot
counting test [9]; and digit span [11]. The tests were per-
formed at baseline (week 0) and at the end of weeks 6,
12, 14, 20, 26 and 28 (Fig. 1). Adverse events were
recorded throughout the study to monitor safety.
Statistical analysis
Analysis of each outcome variable was pre-specified and
followed the principles described by Jones and Kenward
[12] for the analysis of 2 × 2 cross-over trials with a
baseline measurement in each period. Since a number of
the outcome variables have floor and ceiling effects and
are not normally distributed, bias-corrected and acceler-
ated bootstrap confidence intervals (CIs) calculated from
2000 bootstrap samples were used throughout and used
to assess whether results were statistically significant.
For each variable, two tests for carry-over were per-
formed prior to assessing treatment efficacy. First, a test
for carry-over was carried out using the baseline values
immediately prior to each period alone. Second, a stand-
ard test of a direct treatment-by-period interaction
(which can also be interpreted as a test for carry-over)
was carried out using the changes from baseline to 12
weeks.
If either of the tests for carry-over was statistically sig-
nificant (p < 0.05, two-sided, assessed from the bootstrap
CI), then tests of treatment efficacy were carried out by
comparing changes from baseline in the first period
alone. The primary analysis was a t test (with bootstrap
CI) comparing changes from baseline to 12 weeks in the
donepezil and placebo groups. A secondary analysis
compared analogous changes from baseline to 6 weeks.
If neither of the tests for carry-over yielded statistically
significant results, then the treatment effect was esti-
mated ignoring the baseline measures and using the
standard approach to the analysis of a 2 × 2 cross-over
trial. This standard approach used a repeated-measures
two-way analysis of variance model (with bootstrap CI)
with period and treatment as the predictor variables.
This permits a within-subject, period-adjusted treatment
effect to be estimated. The primary analysis used the 12-
week data alone and a secondary analysis used the 6-
week data alone.
Results
Participant characteristics
Eighteen patients were screened and met the inclusion
and exclusion criteria. The mean age was 61.6 years
(range 50–74), and the male:female ratio was 5:13.
Table 2 presents baseline characteristics according to the
randomisation group.
AD pathology was confirmed at post-mortem in two
patients who completed the study and donated their
brain to the Queen Square Brain Bank for Neurological
Disorders, UCL Institute of Neurology, London, UK.
Lumbar puncture done during clinical diagnostic work-
up on one of the patients revealed normal total CSF Tau
concentration at 566 ng/ml and low CSF Aβ1–42 concen-
tration at 206 ng/ml, supportive of the presence of AD
pathology.
Protocol violation and participant withdrawal
The protocol was not followed correctly for one female
participant aged 58 years. Instead of increasing the dose
from level-one treatment to level-two treatment during
the first treatment period at the end of week 6, the
Table 1 Inclusion and exclusion criteria
Inclusion criteria
1. Clinical diagnosis of PCA based on clinical presentation and formal
neuropsychological assessment suggestive of significant visuo-
perceptual or visuo-spatial disturbance, visual disorientation, apraxia,
dysgraphia or dyscalculia in the context of relatively preserved memory
2. Performance below the 5th percentile on two of the following four
tests of parietal lobe function:
• Jackson and Warrington calculation test [21]
• number location visual spatial test [9]
• object decision visual perceptual test [9]
• Baxter and Warrington spelling test [22]
3. Verbal memory test score above the 5th percentile on a
neuropsychological assessment such as the verbal recognition
memory test [23]
4. Absence of alternative cause of cognitive impairment based on
clinical history and examination, and available investigations including
blood tests, electroencephalograph, MRI of brain and formal
neuropsychological assessment
Exclusion criteria
1. Significant neurological or psychiatric disease that may affect
cognition other than Alzheimer’s disease
2. Significant systemic disease that may deteriorate or affect the
patient’s safety or the ability to cooperate with the study protocol
3. Medications with the potential to affect cognition unless maintained
on a stable dose for at least 3 months prior to week 0 visit
4. Patients with lactose intolerance
5. Known hypersensitivity to donepezil hydrochloride, piperidine
derivatives, or to any excipients used in the formulations
MRI magnetic resonance imaging, PCA posterior cortical atrophy
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patient was erroneously given level-one treatment of the
cross-over second treatment period. The error was dis-
covered at the week 14 visit. A decision was taken to
maintain her on level-two treatment of the second treat-
ment period over the following 6 weeks. The intention
was to repeat level-one and level-two treatments of the
first treatment period of the study after a 2-week wash-
out period. However, the patient decided to withdraw
from the trial due to the development of gastrointestinal
side effects soon after repeating level-one treatment of
the first treatment period.
We present the results analysed according to the prin-
ciples of intention to treat (ITT) with the patient’s data
included up to the point at which she withdrew and ana-
lysed according to the treatment that she should have
received at each visit. We also performed per-protocol
analysis with this patient’s data omitted from the point
at which the wrong treatment was given. As there was
no significant difference between the two analysis
methods, only the ITT analysis will be presented.
Mini-Mental State Examination
There was statistically significant (p < 0.05) evidence of
carry-over from the comparison of values immediately
prior to each treatment period (Table 3). Mean baseline
MMSE score of patients randomised to placebo in the
first treatment period was 23.9, and at the end of the
washout period was 23.7. Mean baseline MMSE score of
patients randomised to donepezil in the first treatment
period was 22.6, and at the end of the washout prior to
starting placebo was 25.1 (Figs. 2a and 3).
Because of this evidence of carry-over, efficacy was
assessed by comparing changes in the first treatment
period only. The treatment effect at 12 weeks was not
statistically significant but close (2.0 in favour of
donepezil, 95% CI –0.1 to 4.5), whilst that at 6 weeks
was just statistically significant (2.5 in favour of donepe-
zil, 95% CI 0.1 to 5.0) (Table 3, Fig. 2a).
Simple calculation test
There was statistically significant evidence of carry-over
from the comparison of values immediately prior to each
treatment period (Table 3). Therefore, treatment effects
were assessed by comparing changes in the first treat-
ment period only. Treatment effects at 6 and 12 weeks
were not statistically significant (Table 3, Fig. 2b).
Number location spatial test
Tests for carry-over were not statistically significant
(Table 3). Therefore, treatment effects were estimated
using the standard approach to the analysis of a cross-
over trial. There was no statistically significant difference
at 6 or 12 weeks of treatment (Table 3, Fig. 2c).
Letter cancellation test
Tests for carry-over were not statistically significant
(Table 3). Therefore, treatment effects were estimated in
the standard approach to the analysis of a cross-over
trial. There was no statistically significant difference at 6
or 12 weeks of treatment (Table 3, Fig. 2d).
Dot counting test
Tests for carry-over were not statistically significant
(Table 3). Therefore, treatment effects were estimated in
the standard approach to the analysis of a cross-over
trial. There was no statistically significant difference at 6
or 12 weeks of treatment (Table 3, Fig. 2e).
Digit span
Tests for carry-over were not statistically significant
(Table 3). Therefore, treatment effects were estimated in
the standard approach to the analysis of a cross-over
trial. There was no statistically significant difference at 6
weeks of treatment. After adjusting for period effects,
the mean digit span was 0.5 digits higher at 12 weeks
when patients were receiving placebo (Table 3, Fig. 2f ).
Safety results
There were no serious adverse reactions reported. One
patient discontinued the study due to abdominal cramps
and nausea.
The following side effects were reported and are pre-
sented in order of frequency:
1. Gastrointestinal side effects (nausea, abdominal
cramps, diarrhoea) occurred in 13 subjects (72%):
seven (39%) only whilst on donepezil, four (22%)
only whilst on placebo and two (11%) during both
treatment periods. One of these two subjects was
Table 2 Baseline characteristics of randomised groups
Placebo then donepezil
(n = 10)
Donepezil then placebo
(n = 8)
Gender 4 male, 6 female 1 male, 7 female
Handedness 10 right 3 left, 5 right
Age (years) 60.2 (7.3) 62.9 (6.0)
Disease duration
(years)
3.3 (1.9)a 3.7 (1.5)
MMSE 23.9 (4.0) 22.6 (3.2)
Simple calculation 6.9 (1.4)b 7.3 (1.0)a
Number location 3.9 (2.8) 3.8 (2.9)
Letter cancellation 59.8 (21.5) 91.9 (19.7)
Dot counting 5.3 (2.6)a 5.1 (3.6)a
Digit span 13.4 (3.0)a 13.6 (4.4)a
Data presented as mean (standard deviation) unless otherwise stated
MMSE Mini-Mental State Examination
aOne missing value
bTwo missing values
Ridha et al. Alzheimer's Research & Therapy  (2018) 10:44 Page 4 of 9
Ta
b
le
3
Su
m
m
ar
y
of
da
ta
an
al
ys
is
of
ch
an
ge
s
in
M
M
SE
an
d
fiv
e
ne
ur
op
sy
ch
om
et
ric
te
st
s
re
fle
ct
in
g
pa
rie
to
-o
cc
ip
ita
lf
un
ct
io
n
C
ha
ng
e
fro
m
ba
se
lin
e
of
fir
st
tr
ea
tm
en
t
pe
rio
d
to
ba
se
lin
e
vi
si
t
of
se
co
nd
tr
ea
tm
en
t
pe
rio
d
(t
es
t
of
ca
rr
y-
ov
er
fro
m
ba
se
lin
e
va
lu
es
)
Fi
rs
t
tr
ea
tm
en
t
pe
rio
d:
ch
an
ge
fro
m
ba
se
lin
e
vi
si
t
to
w
ee
k
6
vi
si
t
Fi
rs
t
tr
ea
tm
en
t
pe
rio
d:
ch
an
ge
fro
m
ba
se
lin
e
vi
si
t
to
w
ee
k
12
vi
si
t
D
on
ep
ez
il
(n
=
8)
,
m
ea
n
(S
D
)
Pl
ac
eb
o
(n
=
10
),
m
ea
n
(S
D
)
D
iff
er
en
ce
(9
5%
C
I)
D
on
ep
ez
il
(n
=
8)
,
m
ea
n
(S
D
)
Pl
ac
eb
o
(n
=
10
),
m
ea
n
(S
D
)
D
iff
er
en
ce
(9
5%
C
I)
D
on
ep
ez
il
(n
=
8)
,
m
ea
n
(S
D
)
Pl
ac
eb
o
(n
=
10
),
m
ea
n
(S
D
)
D
iff
er
en
ce
(9
5%
C
I)
M
M
SE
2.
5
(1
.4
)
−
0.
2
(1
.7
)
2.
7
(1
.3
,4
.0
)
1.
0
(3
.1
)
−
1.
5
(2
.4
)
2.
5
(0
.1
,5
.0
)
1.
5
(2
.7
)
−
0.
5
(2
.4
)
2.
0
(−
0.
1,
4.
5)
Si
m
pl
e
ca
lc
ul
at
io
n
−
0.
9
(0
.7
)a
0.
6
(1
.1
)b
−
1.
5
(−
2.
6,
–0
.8
)c
−
0.
1
(0
.7
)a
−
0.
1
(0
.8
)b
–0
.0
(−
0.
7,
0.
8)
c
0.
0
(1
.3
)a
0.
4
(1
.1
)b
−
0.
4
(−
1.
4,
0.
8)
c
D
on
ep
ez
il
vs
pl
ac
eb
o
6-
w
ee
k
co
m
pa
ris
on
D
on
ep
ez
il
vs
pl
ac
eb
o
12
-w
ee
k
co
m
pa
ris
on
D
on
ep
ez
il
fir
st
(n
=
8)
,m
ea
n
(S
D
)
Pl
ac
eb
o
fir
st
(n
=
10
),
m
ea
n
(S
D
)
C
om
bi
ne
d
(n
=
18
),
m
ea
n
(9
5%
C
I)
D
on
ep
ez
il
fir
st
(n
=
8)
,m
ea
n
(S
D
)
Pl
ac
eb
o
fir
st
(n
=
10
),
m
ea
n
(S
D
)
C
om
bi
ne
d
(n
=
18
),
m
ea
n
(9
5%
C
I)
N
um
be
r
lo
ca
tio
n
−
1.
0
(2
.2
)
−
0.
9
(1
.3
)
−
0.
1
(−
1.
7,
1.
5)
0.
8
(1
.8
)
0.
2
(1
.5
)
0.
5
(−
0.
1,
1.
5)
0.
0
(2
.4
)a
0.
7
(2
.4
)
0.
4
(−
0.
8,
1.
4)
a
Le
tt
er
ca
nc
el
la
tio
n
−
0
(2
5)
a
2
(2
1)
−
2
(−
22
,1
9)
a
−
7
(3
9)
−
3
(1
5)
−
5
(−
19
,8
)
−
14
(3
5)
a
−
1
(1
4)
−
8
(−
23
,4
)a
D
ot
co
un
tin
g
−
0.
3
(1
.5
)a
−
1.
0
(2
.4
)a
0.
7
(−
1.
4,
2.
3)
b
1.
3
(1
.8
)
−
0.
2
(1
.3
)a
0.
5
(−
0.
2,
1.
2)
a
1.
3
(0
.8
)a
−
0.
1
(1
.7
)
0.
6
(−
0.
1,
1.
1)
a
D
ig
it
sp
an
0.
3
(1
.5
)b
0.
0
(1
.3
)b
0.
3
(−
0.
9,
2.
0)
d
0.
6
(1
.9
)
0.
1
(1
.6
)
0.
4
(−
0.
4,
1.
2)
0.
0
(1
.0
)a
−
1
(0
.8
)
−
0.
5
(−
0.
9,
−
0.
1)
a
CI
co
nf
id
en
ce
in
te
rv
al
,M
M
SE
M
in
i-M
en
ta
lS
ta
te
Ex
am
in
at
io
n,
SD
st
an
da
rd
de
vi
at
io
n
a O
ne
m
is
si
ng
va
lu
e
b
Tw
o
m
is
si
ng
va
lu
es
c T
hr
ee
m
is
si
ng
va
lu
es
d
Fo
ur
m
is
si
ng
va
lu
es
Ridha et al. Alzheimer's Research & Therapy  (2018) 10:44 Page 5 of 9
the one in whom the protocol was not followed
correctly. The subject only reported gastrointestinal
side effects whilst on donepezil, and ultimately
discontinued because of these.
2. Nightmares and vivid dreams occurred in eight
(44%) subjects: seven (39%) only whilst on donepezil,
one (6%) during both treatment periods and none
only whilst on placebo.
3. Anxiety/low mood occurred in six (33%) subjects:
three (17%) only whilst on donepezil, one (6%) only
whilst on placebo and two (11%) during both
treatment periods.
a b
c d
e f
Fig. 2 Mean value of outcome measures at different time points: (a) MMSE, (b) simple calculation test, (c) number location test, (d) letter
cancellation test, (e) dot counting, (f) digit span. MMSE Mini-Mental State Examination
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4. Headache occurred in five (28%) subjects: one (6%)
only whilst on donepezil, two (11%) only whilst on
placebo and two (11%) during both treatment
periods.
5. Dizziness occurred in three (17%) subjects: one (6%)
whilst on donepezil, one (6%) only whilst on placebo
and one (1%) during both treatment periods.
6. Muscular aches, pains and/or jerking movements
occurred in three (17%) subjects: two (11%) only
whilst on donepezil and one (6%) only whilst on
placebo.
Out of these, the only statistically significant side effect
was nightmares and vivid dreams, which occurred more
frequently during donepezil than placebo treatment pe-
riods (p = 0.02, McNemar’s test, Fisher’s exact p value).
Discussion
All patients screened met the inclusion and exclusion
criteria. Patients with PCA due to underlying AD were
already known to the clinical investigators as they were
under their clinical care. This allowed rigorous pre-
screening based on their clinical assessment, and so only
patients who were highly likely to fulfil the study criteria
were invited to participate.
The study was conducted over a long period (8.7
years). This reflected the relative rarity of this atypical
variant of AD and the difficulties in identifying drug-
naïve subjects who have not yet been started on a cho-
linesterase inhibitor.
As would be anticipated in a small trial, some baseline
imbalances were seen, with the imbalance in baseline let-
ter cancellation scores being the most marked. Since this
is a cross-over trial, with each patient acting as their
own control, these imbalances matter much less than
would be the case in a parallel-group trial. In our ana-
lysis we could have additionally adjusted for the baseline
values made immediately prior to each period, but did
not do so, preferring to use the method we had pre-
specified in our statistical analysis plan as recommended
in the then current edition of Jones and Kenward [12].
In our primary analysis there was no statistically sig-
nificant treatment effect of donepezil on the primary
outcome measure: change in MMSE at 12 weeks. How-
ever, since this is a small cross-over trial, all of our re-
sults, both positive and negative, must be interpreted
cautiously. Some of our results do provide evidence for a
beneficial effect of donepezil on MMSE in patients with
PCA due to underlying AD. Firstly, there was statistically
significant evidence of a carry-over effect suggesting that
the effect of donepezil may have continued after the 2-
week washout period, with the largest effects only being
seen after the washout period. Secondly, during the first
treatment period, there was statistically significant differ-
ence in the change in the MMSE at 6 weeks (MMSE
difference = 2.5, 95% CI 0.1 to 5.0, p < 0.05). We reiter-
ate, however, that the small sample size, the borderline
nature of the statistical results, and the fact that the dir-
ection of the baseline imbalance coupled with regression
to the mean are likely to have exaggerated the differ-
ences and mean that the results should be interpreted
cautiously.
There was no statistically significant improvement in
any of the neuropsychological tests relating to parieto-
occipital function as a result of treatment with donepezil
in patients with PCA due to underlying AD. In fact,
Fig. 3 Individual MMSE trajectories. MMSE Mini-Mental State Examination
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there was statistically significant evidence for a slight
reduction of digit span by 0.5 digits (p < 0.05) after 12
weeks of treatment with donepezil. However, this result
should be interpreted cautiously in view of the number
of statistical tests carried out and the consequent
increased risk of false positive findings.
The most commonly reported adverse events were
gastrointestinal (nausea, abdominal cramps or diar-
rhoea), affecting 67% of patients. These are well-
recognised side effects of donepezil. Safety data from
one phase II trial and three phase III trials revealed that
gastrointestinal side effects occurred in 44% of patients
receiving 10 mg donepezil compared to 22% of patients
receiving placebo [13].
A study by Farlow et al. [14] identified an increased
incidence of adverse events in patients with weight
below 55 kg compared with those with higher weights.
Although our study used significantly lower daily doses
of donepezil of 5 mg and 10 mg, it would have been
helpful to have recorded subjects’ weights in case weight
still influenced the risk of developing side effects at these
lower doses.
Nightmares and vivid dreams have been reported to
occur in AD patients who have been prescribed donepe-
zil, particularly if taken close to bedtime, and resolved
once discontinued or when dosing time was changed to
the morning [15–17].
Of our patients with PCA due to underlying AD, 44%
experienced nightmares or vivid dream whilst taking
donepezil and none during the placebo period alone.
Singer et al. [17] reported nightmares to occur in eight
out of 103 (8%) AD patients. Previous clinical trials of
donepezil in AD found that insomnia and other sleep-
related symptoms occurred in 8–18% of patients receiv-
ing donepezil compared with 4–6% of patients receiving
placebo [18–20]. The higher incidence of nightmare and
vivid dreams in our study may indicate that patients with
PCA due to underlying AD may be particularly suscep-
tible for the development of nightmares and vivid
dreams due to disproportionate parieto-occipital dys-
function in this patient group.
There are several limitations to this study. The sample
size of the study is small. PCA is relatively rare so it was
challenging to find patients fulfilling the specified inclu-
sion/exclusion criteria at a single site. AD is not the only
cause of a clinical presentation of PCA; therefore the
diagnosis of AD as the underlying cause of PCA is at
best probable. With one exception, participating patients
did not have CSF Tau and Aβ1–42 measurement or amyl-
oid PET imaging as in-vivo biomarkers for the presence
of AD pathology. However, AD was pathologically
confirmed in two of the participating patients who sub-
sequently died. Other conditions that can present with
PCA include dementia with Lewy bodies, corticobasal
degeneration and prion disease. None of our patients
exhibited any neurological features to suggest any of
these. Although this was a double-blind trial, the fre-
quent occurrence of predictable side effects such as
gastrointestinal side effects may have caused patients
and clinical investigators to sometimes guess what treat-
ment they were on. The washout period may have been
too short, as evidenced by the carry-over effect on the
MMSE and simple calculation test. The outcome mea-
sures are relatively crude, variable and influenced by
patient and rater factors. In addition, learning may have
occurred due to repeated testing over a short study
period. The improvement in the MMSE rather than spe-
cific tests of biparietal function may relate to subtle
improvements in relatively spared cognitive domains
such as episodic memory and orientation, which are the
MMSE’s predominant focus.
Conclusions
This small, double-blind, placebo-controlled, cross-over
study found no statistically significant treatment effect
on the MMSE at 12 weeks (primary outcome measure)
in patients with PCA.
Known common gastrointestinal side effects of done-
pezil occurred in the course of the study. The frequency
of nightmares and vivid dreams occurred significantly
more commonly in association with donepezil treat-
ment, and possibly more commonly than reported previ-
ously in patients with the typical amnestic presentation
of AD. Patients with PCA may be particularly vulnerable
to these side effects.
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